Inotuzumab Ozogamicin Versus Standard Care for Acute Lymphoblastic Leukemia

BACKGROUND: Inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, is active in acute lymphoblastic leukemia. METHODS: In this phase 3 trial, adults with relapsed/refractory acute lymphoblastic leukemia were randomized to inotuzumab ozogamicin or standard intensive chemotherapy. P...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:N Engl J Med
Prif Awduron: Kantarjian, Hagop M., DeAngelo, Daniel J., Stelljes, Matthias, Martinelli, Giovanni, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, O’Brien, Susan, Wang, Kongming, Wang, Tao, Paccagnella, M. Luisa, Sleight, Barbara, Vandendries, Erik, Advani, Anjali S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5594743/
https://ncbi.nlm.nih.gov/pubmed/27292104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1509277
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg